Clinical Trials for Paclitaxel
10 Open Trials
| Trial Type | Protocol No. & Open Date | Summary |
|---|---|---|
| Therapeutic | ECOGGIR1010 02/28/2013 | A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma |
| Therapeutic | VICCGI1283 02/14/2013 | A Randomized, Multicenter, Adaptive Phase II/III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel or Paclitaxel) in Patients with Previously Treated Locally Advanced or Metastatic HER2-Positive Gastric Cancer, Including Adenocarcinoma of the Gastroesophageal Junction |
| Therapeutic | VICCMEL12100 01/18/2013 | A Randomized, Open-Label Phase 3 Trial of BMS-936558 versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy. |
| Therapeutic | VICCBRE1270 11/20/2012 | A Phase II, Multi-Center, Open-Label, Neoadjuvant, Randomized Study of Weekly Paclitaxel with or without LCL161 in Patients with Triple Negative Breast Cancer |
| Therapeutic | VICCGYN1206 09/25/2012 | A phase II randomized open label study of MM-121 in combination with paclitaxel versus paclitaxel alone in patients with platinum resistant/refractory advanced ovarian cancers |
| Therapeutic | VICCBRE1202 05/04/2012 | A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of PI3-Kinase Inhibitor GDC-0941 in Combination with Paclitaxel, With and Without Bevacizumab or Trastuzumab, in Patients with Locally Recurrent or Metastatic Breast Cancer |
| Therapeutic | VICCBRE1157 05/01/2012 | A Randomized Multicenter, Double-blind, Placebo-Controlled Comparison of Chemotherapy plus Trastuzumab plus Placebo versus Chemotherapy plus Trastuzumab plus Pertuzumab as Adjuvant Therapy in Patients with operable HER2-Positive Primary Breast Cancer |
| Therapeutic | ECOGBRES1007 01/10/2012 | A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor Positive and Her 2 Neu Negative Breast Cancer with Recurrence Score of 25 or Less. |
| Therapeutic | ECOGTHNE5508 06/29/2011 | Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Premetrexed, or Combination of Bevacizumab and Premtrexed following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC |
| Therapeutic | ECOGTHO4508-M 12/07/2010 | Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12 or Both for Advanced Non-small Cell Lung Cancer Patients WhoWill Not Receive Bevacizumab-based Therapy |
You do not have JavaScript enabled. This site works better with JavaScript turned on.
